Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

On Wednesday, pharmaceutical giant Eli Lilly sued four prominent telehealth companies that offer more affordable, off-brand versions of its patented best-selling GLP-1 medications Mounjaro and ...

However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—commonly used in treating type 2 diabetes and obesity—may offer new promise in treating AUD.

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from their spending on such drugs five years earlier, according to a research ...

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model ...

The Monell team and colleagues identified that GLP-1 receptor agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic ...